IgA Nephropathy: Prognosis and Current Therapies in 2025
Nov, 10 2025
IgA Nephropathy is not just another kidney condition-it’s a silent, progressive disease that can turn a young, active person’s life upside down. First identified in 1968, it’s now the most common cause of primary glomerulonephritis worldwide, especially in Asia, where it affects up to half of all patients with kidney inflammation. The problem? Many people don’t know they have it until their kidneys are already damaged. By the time symptoms like dark urine or swelling appear, years of hidden damage may have occurred. But in 2025, the game has changed. New guidelines, new drugs, and a sharper understanding of risk are making it possible to stop this disease before it leads to dialysis or transplant.
What IgA Nephropathy Really Does to Your Kidneys
IgA Nephropathy happens when your immune system makes faulty antibodies-specifically, immunoglobulin A (IgA)-that clump together and get stuck in the filtering units of your kidneys, called glomeruli. These clumps trigger inflammation. Over time, that inflammation scars the filters. Once scarred, they can’t clean your blood properly. Protein leaks into your urine (proteinuria), blood shows up in your urine (hematuria), and your kidney function slowly drops.
What makes it tricky is that it doesn’t always cause obvious symptoms. About 30-40% of people are diagnosed only after a routine urine test finds tiny amounts of blood or protein. Others notice dark, cola-colored urine after a cold or sore throat-a classic sign that IgA is reacting to a mucosal infection. The disease usually hits people between ages 16 and 35, but it can occur at any age. And while it’s not contagious or inherited in a simple way, family history does increase risk.
Prognosis: How Bad Will It Get?
Here’s the hard truth: about half of all people with IgA Nephropathy will develop kidney failure within 10 to 20 years if nothing is done. That’s why prognosis isn’t about the diagnosis-it’s about how much protein you’re losing in your urine and how fast your kidney function is dropping. The old rule was that proteinuria under 1 gram per day was acceptable. That’s changed.
According to the KDIGO 2025 guidelines, the new target is less than 0.5 grams per day. Why? Because even people with proteinuria between 0.44 and 0.88 g/g creatinine still had a 30% chance of kidney failure within 10 years. That means if you’re still losing more than half a gram of protein daily, your kidneys are still under siege. Blood pressure control matters too-keeping it below 120/80 mmHg slows damage. Your eGFR (estimated glomerular filtration rate) is another key number. If it’s falling more than 5 mL/min/year, your risk is high.
But numbers alone don’t tell the whole story. The Oxford MEST-C score, based on a kidney biopsy, looks at four types of damage: mesangial hypercellularity, endocapillary proliferation, segmental sclerosis, and tubular atrophy. If your biopsy shows multiple signs of scarring, your prognosis worsens-even if your proteinuria is moderate.
Current Therapies: What Works Now in 2025
The old way of treating IgA Nephropathy was slow. Doctors would start with blood pressure meds-usually ACE inhibitors or ARBs-and wait three months to see if proteinuria dropped. If it didn’t, they’d add steroids or other immunosuppressants. That waiting period? It was a mistake. While you waited, the IgA deposits kept damaging your kidneys.
The KDIGO 2025 guidelines flipped the script. Now, for high-risk patients, you start everything at once:
- RAS inhibitors (ACEi or ARB) to reduce proteinuria and blood pressure
- SGLT2 inhibitors (like dapagliflozin or empagliflozin) to protect kidney cells and lower glucose
- Targeted therapy: Nefecon-a capsule that releases budesonide directly in the gut, where faulty IgA is made. It cuts production at the source.
- Systemic steroids (like prednisone) for those who can’t access or tolerate Nefecon
- DEARA (sparsentan), a dual endothelin-angiotensin blocker, approved in Europe in 2024 for high-risk cases
Nefecon, approved by the FDA in December 2023, is the first drug designed specifically for IgA Nephropathy. In trials, it cut proteinuria by 35-40% in 9 months, with fewer side effects than oral steroids. But it’s expensive-$125,000 a year in the U.S. Many patients face insurance denials. In contrast, systemic steroids are cheaper but come with weight gain, mood swings, diabetes risk, and bone loss. For many, Nefecon is the better option-if they can get it.
Regional differences matter. In Japan, tonsillectomy is common because throat infections often trigger IgA flares. In China, mycophenolate mofetil and hydroxychloroquine are used more often than in the West. But these approaches haven’t been proven effective in U.S. or European trials, so they’re not in the global guidelines.
What Doesn’t Work Anymore
Don’t waste time on unproven treatments. Fish oil? A few older studies suggested benefit, but newer data shows no clear effect on kidney outcomes. Immunosuppressants like cyclophosphamide or azathioprine? Too risky for IgAN-side effects outweigh benefits. And don’t delay treatment waiting for a “perfect” time. The longer you wait to start therapy, the more scarring you accumulate.
Also, avoid assuming that “mild” proteinuria means “mild” disease. One patient I know, a 28-year-old teacher, had proteinuria at 0.6 g/day. She thought she was fine. Two years later, her eGFR dropped 30%. She needed Nefecon and SGLT2i immediately-but the damage was already done.
Monitoring and Lifestyle: The Daily Fight
Managing IgA Nephropathy isn’t just about pills. It’s about daily habits.
- Check urine protein monthly during the first 3 months of treatment, then quarterly
- Track blood pressure daily-home monitoring is better than clinic readings
- Limit salt to under 2,000 mg per day
- Avoid NSAIDs like ibuprofen-they stress your kidneys
- Stay active but avoid extreme exertion during flares
- Get vaccinated-flu, pneumonia, and COVID vaccines reduce infection-triggered flares
Patients who stick to these habits and take their meds consistently have the best outcomes. One 2025 study showed that patients who maintained proteinuria below 0.5 g/day for two years had a 90% lower risk of kidney failure compared to those who didn’t.
Challenges and Real-World Barriers
The new guidelines are groundbreaking-but they’re not easy to follow. In the U.S., only 42% of nephrology clinics had fully adopted the KDIGO 2025 protocols six months after release. Why? It’s complicated. Doctors need training to use the risk calculator. Pharmacists struggle with prior authorizations for Nefecon. Patients get overwhelmed by taking four medications at once.
Cost is a huge barrier. Nefecon costs $125,000 a year. Even with insurance, many patients pay $5,000-$10,000 out of pocket. In low- and middle-income countries, less than 22% of patients get guideline-recommended care. That’s not just unfair-it’s deadly.
And we still don’t know who will respond best to which drug. Is it the person with high gut IgA production? The one with complement system overactivity? We’re close to biomarker-guided therapy-trials like TARGET-IgAN are testing this right now-but we’re not there yet.
What’s Coming Next
The future is personalization. By 2027, the TARGET-IgAN study will test whether we can match patients to treatments based on blood and urine biomarkers-not just protein levels and biopsy results. New drugs are in phase 3 trials: Ulotaront (targeting APRIL, a protein that drives IgA production), and anti-complement therapies like iptacopan. These could offer alternatives for people who can’t tolerate steroids or can’t afford Nefecon.
Also, the NEPTUNE registry is expanding to include 5,000 more patients worldwide. This real-world data will help us understand how treatments work outside clinical trials-especially in diverse populations.
The goal isn’t just to delay kidney failure. It’s to let people live full, active lives without constant fear. That means minimizing side effects, reducing pill burden, and making treatments affordable. The science is moving fast. The challenge now is making sure no one is left behind.
Can IgA Nephropathy be cured?
No, there is no cure for IgA Nephropathy yet. But with the right treatment-especially starting early and hitting the new proteinuria target of less than 0.5 g/day-many people can stop or dramatically slow the disease. Some patients achieve long-term remission, meaning their kidneys function normally for decades without progression.
Is Nefecon better than steroids?
For most patients, yes. Nefecon targets the source of faulty IgA in the gut and has fewer side effects than oral steroids. In surveys, 72% of patients reported fewer side effects with Nefecon. Steroids can cause weight gain, mood changes, diabetes, and bone loss. Nefecon is more expensive and harder to access, but when available, it’s the preferred first-line immunosuppressant for high-risk patients.
How often should I get my kidneys checked?
When starting treatment, check urine protein and blood pressure every month for the first 3 months. After that, check every 3 months. Your eGFR should be tested at least every 6 months. If your proteinuria drops below 0.5 g/day and stays there for a year, your doctor may extend monitoring to every 6 months. Always report new swelling, fatigue, or dark urine immediately.
Can I still have kids if I have IgA Nephropathy?
Yes, but pregnancy carries risks. High blood pressure and proteinuria increase the chance of preeclampsia and preterm birth. Ideally, you should have proteinuria under 1 g/day and stable kidney function before getting pregnant. Talk to your nephrologist and an obstetrician who specializes in high-risk pregnancies. Some medications, like ACE inhibitors and SGLT2 inhibitors, must be stopped before conception-so planning is essential.
Why is proteinuria the most important number?
Proteinuria is the strongest predictor of kidney failure in IgA Nephropathy. Every time protein leaks into your urine, it’s a sign your kidney filters are damaged. Lowering proteinuria reduces inflammation and slows scarring. Studies show that patients who get proteinuria below 0.5 g/day have up to 90% lower risk of kidney failure over 10 years. That’s why it’s the main goal of every treatment.
Ben Saejun
November 12, 2025 AT 06:49They say IgA Nephropathy is silent, but let’s be real-it screams in the lab results. Proteinuria under 0.5 g/day? That’s not a target, it’s a lifeline. I’ve seen people ignore it until their eGFR tanked, then wonder why they’re on dialysis. The science isn’t new, but the urgency is. Stop waiting for symptoms. Start treating the numbers before they become your obituary.
Visvesvaran Subramanian
November 13, 2025 AT 22:45Doctors in India still use mycophenolate and hydroxychloroquine because Nefecon is out of reach for 95% of patients. Guidelines are beautiful on paper. In reality, we treat with what we have. If a patient survives 10 years with low-cost meds and strict salt control, that’s a win. Progress shouldn’t be measured in dollars but in lives touched.
Christy Devall
November 14, 2025 AT 05:55They call it a silent disease. I call it the quiet thief. It steals your future one protein molecule at a time while you’re scrolling through memes thinking you’re fine. And then there’s Nefecon-$125K a year to fix what we broke by ignoring early warning signs. We’ve created a system where salvation is a luxury item. That’s not medicine. That’s moral bankruptcy dressed in white coats.
Selvi Vetrivel
November 14, 2025 AT 08:29So let me get this straight-we have a drug that targets IgA production at the source, but only if you’re rich enough to fight your insurance company for six months? Meanwhile, tonsillectomies in Japan are cheaper and work just as well. Funny how Western medicine loves expensive gadgets but hates simple solutions. Maybe we should’ve listened to the Ayurvedic doctors instead of the pharma reps.
Nick Ness
November 15, 2025 AT 16:58It is imperative to underscore that the KDIGO 2025 guidelines represent a paradigmatic shift in the clinical management of IgA nephropathy. The integration of SGLT2 inhibitors and targeted gut-directed therapy constitutes a significant advancement in renoprotection. However, adherence to these protocols requires multidisciplinary coordination, including nephrology, pharmacy, and primary care integration. Without standardized implementation frameworks, disparities in care will persist, particularly in underserved populations.
Rahul danve
November 15, 2025 AT 22:22LOL Nefecon? 😂 Bro, you’re telling me we spent 50 years treating kidneys like broken sinks and now we’re just now fixing the faucet? Meanwhile, my cousin in Kerala had a tonsillectomy at 18 and hasn’t had a flare since. But nooo, let’s sell a $125K pill to Americans who think ‘gut health’ is a TikTok trend. The real cure? Stop pretending medicine is about science and admit it’s about profit.
Abbigael Wilson
November 17, 2025 AT 04:23One cannot help but observe the staggering epistemological dissonance inherent in contemporary nephrology. The KDIGO 2025 paradigm, while ostensibly evidence-based, remains tragically reductionist-reducing a complex immunoglobulin-mediated glomerulopathy to a binary metric of proteinuria. The MEST-C score, a veritable Rosetta Stone of histopathological nuance, is all but ignored in favor of algorithmic risk stratification. And Nefecon? A pharmacological ballet performed on the stage of capitalist healthcare, where access is determined not by clinical need, but by insurance tier.
Katie Mallett
November 17, 2025 AT 09:37For anyone newly diagnosed: you’re not alone. I was told I’d be on dialysis by 40. Now, at 34, I’m on Nefecon + SGLT2i, my proteinuria is at 0.3 g/day, and I hike every weekend. It’s not easy. You’ll hate the pills. You’ll cry over bills. But you can still live. Track your numbers. Talk to your doctor. Find a support group. This disease doesn’t define you-it just changes how you show up for your life.
Joyce Messias
November 17, 2025 AT 21:18My mom has IgAN. She’s 62. We started her on ARB + SGLT2i after her biopsy showed MEST-C score E1S1. No steroids. No Nefecon-too expensive. But she’s been stable for 18 months. She walks 5K steps daily. She cooks low-sodium meals. She checks her BP every morning. No fancy tech. Just consistency. If you’re reading this and scared-start here. Not with the most expensive drug. With the most consistent habit.
Wendy Noellette
November 18, 2025 AT 01:53It is essential to emphasize that the reduction of proteinuria to below 0.5 g/day remains the most robustly validated therapeutic endpoint in IgA nephropathy, as corroborated by multiple longitudinal cohort studies including NEPTUNE and CREDENCE subanalyses. The advent of Nefecon represents a significant pharmacological innovation; however, its cost-effectiveness remains under evaluation in health economic models. Clinicians are urged to adhere strictly to risk stratification protocols to ensure appropriate patient selection.
Devon Harker
November 19, 2025 AT 20:26People act like IgA Nephropathy is some mysterious curse. Nah. It’s what happens when you eat junk, ignore your urine, and let your doctor wait three months before doing anything. You think Nefecon is expensive? Try paying for dialysis for 20 years. Stop being lazy. Start treating it. And if you can’t afford it? Then maybe you shouldn’t have spent your paycheck on crypto and Uber Eats.
Walter Baeck
November 21, 2025 AT 01:16I’ve been living with this for 12 years. I’ve been on everything-steroids, cyclosporine, fish oil (which did nothing), and now Nefecon. Let me tell you something: the real battle isn’t the disease. It’s the system. The insurance denials. The 3-month wait for prior auth. The pharmacist who says ‘try calling back next week.’ The doctor who says ‘we’ll monitor for now.’ You know what? There’s no ‘now.’ There’s only ‘before’ and ‘after.’ I’m alive because I didn’t wait. I fought. I called. I wrote letters. I screamed. If you’re reading this and you’re scared? Don’t wait. Fight. Even if you’re tired. Even if you’re broke. Even if you feel like no one’s listening. You’re not alone. We’re all just trying to keep our kidneys from becoming museum pieces.
Austin Doughty
November 22, 2025 AT 06:06So Nefecon works? Cool. But why is it only approved in the US and EU? Why not India? Why not Nigeria? Because profit > people. And now we’ve got doctors treating this like a video game-‘level up your proteinuria score to unlock the Nefecon boss battle.’ Meanwhile, real people are dying because their insurance says ‘no.’ This isn’t medicine. It’s a dystopian auction.
Oli Jones
November 24, 2025 AT 04:51In the UK, we’ve got a different kind of silence-the silence of the NHS struggling to keep up. Nefecon? We’re still debating whether to fund it. Steroids? We use them, but the side effects are brutal on older patients. I’ve seen a 24-year-old in Leeds who lost her job because she couldn’t afford the co-pay for her SGLT2 inhibitor. The science is brilliant. But compassion? That’s still optional.